Full Intervention for COVID-19

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Kaiser Permanente Georgia Center for Research and Evaluation, Atlanta, GA
COVID-19+2 More
Full Intervention - Behavioral
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a communication and engagement strategy to see if it increases COVID-19 booster vaccination rates among facility staff. The strategy being tested includes developing materials tailored to staff whose primary language is not English or who are from certain cultural affinity groups, and distributing these materials by members of the same language/cultural affinity groups. The trial is being conducted in Washington state and Georgia. The treatment that will be used to treat COVID-19 is Full Intervention. This treatment has been approved by the FDA for a different condition in the past. The treatment will be done online and no patients in the trial will receive a placebo.

Eligible Conditions

  • COVID-19
  • COVID19 (disease)

Treatment Effectiveness

Study Objectives

2 Primary · 2 Secondary · Reporting Duration: Baseline (Time 0); 7 months post-randomization (Time 1); 10 months post-randomization (Time 2); 13 months post-randomization (Time 3)

Month 13
Change in COVID-19 vaccine attitudes
Change in COVID-19 vaccine confidence
Change in COVID-19 vaccine knowledge
Change in likelihood of recommending COVID-19 vaccination
Change in vaccine hesitancy
Month 13
Change in COVID-19 booster vaccination rate

Trial Safety

Trial Design

2 Treatment Groups

Enhanced Usual Care
1 of 2
Full Intervention
1 of 2
Active Control
Experimental Treatment

5000 Total Participants · 2 Treatment Groups

Primary Treatment: Full Intervention · No Placebo Group · N/A

Full Intervention
Behavioral
Experimental Group · 1 Intervention: Full Intervention · Intervention Types: Behavioral
Enhanced Usual Care
Other
ActiveComparator Group · 1 Intervention: Enhanced Usual Care · Intervention Types: Other

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: baseline (time 0); 7 months post-randomization (time 1); 10 months post-randomization (time 2); 13 months post-randomization (time 3)
Closest Location: Kaiser Permanente Georgia Center for Research and Evaluation · Atlanta, GA
Photo of Atlanta 1Photo of Atlanta 2Photo of Atlanta 3
N/AFirst Recorded Clinical Trial
1 TrialsResearching COVID-19
0 CompletedClinical Trials

Who is running the clinical trial?

Patient-Centered Outcomes Research InstituteOTHER
488 Previous Clinical Trials
29,861,588 Total Patients Enrolled
11 Trials studying COVID-19
509,929 Patients Enrolled for COVID-19
Global Alliance to Prevent Prematurity and Stillbirth (GAPPS)UNKNOWN
Kaiser PermanenteLead Sponsor
497 Previous Clinical Trials
22,181,217 Total Patients Enrolled
5 Trials studying COVID-19
403,269 Patients Enrolled for COVID-19
Clarissa Hsu, PhDPrincipal InvestigatorKaiser Permanente
1 Previous Clinical Trials
418 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 2 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You must be at least 18 years old.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.